Mindy Bixby, DO
Neurology · Laguna Beach, CANPI 1508012139
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $201,636 of the $294,727 with a category attached, or 68.4%. 38 manufacturers reported payments, led by MDD US Operations, LLC at 40.6% of the total. Reporting peaked in 2019 at $137,051 and has fallen 64.2% since, to $49,067 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 985 payments — averaging $299.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$120K
- Amneal Pharmaceuticals LLC$101K
- Abbott$52K
- Zambon USA Ltd.$8K
- AbbVie$6K
- Boston Scientific$4K
- plus $5K from 32 others
Across 22 payments — averaging $7549.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$155K
- Acadia Pharmaceuticals Inc$6K
- MDD US Operations, LLC$5K
What the payments were for
- Consulting fees$37,27713%
- Speaking & faculty fees$201,63668%
- Travel & lodging$37,83713%
- Food & beverage$16,5136%
- Education$1,4630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- APOKYN$89,093
- RYTARY$54,086
- CREXONT$43,382
- INFINITY$26,560
- MYOBLOC$18,270
- Xadago$17,330
- IonicRF Generator$9,275
- Proclaim IPG$7,818
- Infinity DBS Pulse Generators$4,451
- Duopa$2,713
- VERCISE$1,524
- SPECTRA WAVEWRITER$1,010
- PERCEPT PC BRAINSENSE$561
- GENERAL DBS$533
- ACTIVA PC$253
- ACTIVA$148
- QULIPTA$125
- PROCLAIM$123
- XEOMIN$100
How this compares
$294,727 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 274 | $311,088 |
| NuplazidPimavanserin Tartrate | 47 | $222,075 |
| GocovriAmantadine Hcl | 44 | $163,396 |
| IngrezzaValbenazine Tosylate | 11 | $89,696 |
| Droxidopa | 19 | $74,662 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 480 | $27,006 |
| NeuproRotigotine | 11 | $23,462 |
| Nurtec OdtRimegepant Sulfate | 16 | $17,992 |
| OngentysOpicapone | 17 | $17,599 |
| CrexontCarbidopa/Levodopa | 32 | $16,630 |
| Rivastigmine | 71 | $14,485 |
| Rasagiline Mesylate | 59 | $11,183 |
| ExelonRivastigmine | 11 | $7,706 |
| Entacapone | 27 | $7,562 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 55 | $5,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Crexont | $100,674 | $327,718306 claims |
| Acadia Pharmaceuticals IncNuplazid | $269 | $222,07547 claims |
| MDD US Operations, LLCGocovri | $119,582 | $163,39644 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $60 | $107,29528 claims |
| UCB, Inc.Neupro | $41 | $23,46211 claims |
| PfizerNurtec Odt | $27 | $17,99216 claims |
| NovartisExelon | $226 | $7,70611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in Laguna Beach
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.